Evidence map›Paper›PMID 42716948›Full record

ArticleNature communications2026

Recurrent mechanisms of biallelic epigenetic inactivation reveal new putative tumour suppressor genes in prostate cancer.

Daria Kiriy, Francesco Favero, Clarissa Gerhäuser, Jessica Heilmann, Pavlo Lutsik, Francisco German Rodriguez Gonzalez, Alessio Locallo, Jakob Schmidt Jespersen, Andreas J Gruber, Andre V Olsen and 48 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

58 authors.

Daria KiriyThe Finsen Laboratory, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Francesco FaveroThe Finsen Laboratory, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.ORCID http://orcid.org/0000-0003-3684-2659
Clarissa GerhäuserDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-5792-3901
Jessica HeilmannDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Pavlo LutsikDivision of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0001-9383-8555
Francisco German Rodriguez GonzalezThe Finsen Laboratory, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Alessio LocalloThe Finsen Laboratory, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.ORCID http://orcid.org/0000-0003-0977-9586
Jakob Schmidt JespersenThe Finsen Laboratory, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-4930-5900
Andreas J GruberUniversity of Konstanz, Konstanz, Germany.ORCID http://orcid.org/0000-0001-7664-4257
Andre V OlsenThe Finsen Laboratory, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Barbara HernandoSpanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID http://orcid.org/0000-0003-4019-2732
Kevin Cl ChengDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada.
Diogo PellegrinaDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0001-6423-5093
Geoff MacintyreSpanish National Cancer Research Centre (CNIO), Madrid, Spain.ORCID http://orcid.org/0000-0003-3906-467X
G Steven BovaProstate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland; Tays Cancer Center, Tampere University Hospital, Tampere, Finland.ORCID http://orcid.org/0000-0003-1639-3104
Daniel S BrewerNorwich Medical School, University of East Anglia, Norwich Research Park, Norwich, UK.ORCID http://orcid.org/0000-0003-4753-9794
Robert G BristowManchester Cancer Research Centre and Cancer Research UK Manchester Institute, The University of Manchester, 555 Wilmslow Road, Manchester, UK.ORCID http://orcid.org/0000-0002-8553-9544
Mark N BrookThe Institute of Cancer Research, 123 Old Brompton Road, London, UK.ORCID http://orcid.org/0000-0002-8969-2378
Benedikt BrorsDivision Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0001-5940-3101
Adam ButlerWellcome Sanger Institute, Hinxton, Cambridge, UK.
Géraldine Cancel-TassinCeRePP (Centre de Recherche sur les Pathologies Prostatiques et Urologiques), 4 rue de la Chine, Paris, France.ORCID http://orcid.org/0000-0002-9583-6382
Niall M CorcoranDepartment of Surgery, The University of Melbourne, Parkville, VIC, Australia.
Olivier CussenotCeRePP (Centre de Recherche sur les Pathologies Prostatiques et Urologiques), 4 rue de la Chine, Paris, France.
Ros A EelesThe Institute of Cancer Research, 123 Old Brompton Road, London, UK.ORCID http://orcid.org/0000-0002-3698-6241
Abraham GihawiNorwich Medical School, University of East Anglia, Norwich Research Park, Norwich, UK.ORCID http://orcid.org/0000-0002-3676-5561
Etsehiwot G GirmaThe Finsen Laboratory, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Vincent J GnanapragasamDivision of Urology, Department of Surgery, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0003-4722-4207
Anis HamidDepartment of Surgery, The University of Melbourne, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-7193-9723
Vanessa M HayesNorwich Medical School, University of East Anglia, Norwich Research Park, Norwich, UK.ORCID http://orcid.org/0000-0002-4524-7280
Housheng Hansen HeDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0003-2898-3363
Christopher M HovensDepartment of Surgery, The University of Melbourne, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-0610-1289
Eddie L ImadaDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA.
G Maria JakobsdottirChristie Hospital, The Christie NHS Foundation Trust, Manchester, UK.ORCID http://orcid.org/0000-0001-8225-6541
Chol-Hee JungMelbourne Bioinformatics, The University of Melbourne, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-2992-3162
Francesca KhaniDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA.ORCID http://orcid.org/0000-0001-7238-8604
Zsofia Kote-JaraiThe Institute of Cancer Research, 123 Old Brompton Road, London, UK.ORCID http://orcid.org/0000-0002-6329-5155
Philippe P LamyDepartment of Molecular Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus, DK, Denmark.ORCID http://orcid.org/0000-0003-1347-7724
Gregory LeemanWellcome Sanger Institute, Hinxton, Cambridge, UK.ORCID http://orcid.org/0000-0001-5212-6850
Massimo LodaDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA.ORCID http://orcid.org/0000-0001-9674-8379
Luigi MarchionniDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA.ORCID http://orcid.org/0000-0002-7336-8071
Ramyar MolaniaWalter and Eliza Hall Institute of Medical Research, 1G Royal Pde, Parkville, VIC, Australia.
Anthony T PapenfussWalter and Eliza Hall Institute of Medical Research, 1G Royal Pde, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-1102-8506
Bernard PopeDepartment of Surgery, The University of Melbourne, Parkville, VIC, Australia.ORCID http://orcid.org/0000-0002-4840-1095
Lucio R QueirozDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA.ORCID http://orcid.org/0000-0002-6090-1834
Tobias RauschGenome Biology Unit, European Molecular Biology Laboratory (EMBL), Meyerhofstraße 1, Heidelberg, Germany.ORCID http://orcid.org/0000-0001-5773-5620
Brian RobinsonDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA.ORCID http://orcid.org/0000-0001-5374-890X
Atef SahliManchester Cancer Research Centre, The University of Manchester, 555 Wilmslow Road, Manchester, UK.
Karina D SørensenDepartment of Molecular Medicine, Aarhus University Hospital, Palle Juul-Jensens Boulevard 99, Aarhus, DK, Denmark.ORCID http://orcid.org/0000-0002-4902-5490
Sebastian UhrigDivision Applied Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.ORCID http://orcid.org/0000-0002-0068-5957
David C WedgeChristie Hospital, The Christie NHS Foundation Trust, Manchester, UK.ORCID http://orcid.org/0000-0002-7572-3196
Yaobo XuWellcome Sanger Institute, Hinxton, Cambridge, UK.ORCID http://orcid.org/0000-0003-1242-513X
Takafumi N YamaguchiJonsson Comprehensive Cancer Center, University of California - Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA, USA.
Claudio ZanettiniDepartment of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA.ORCID http://orcid.org/0000-0001-5043-8033
Pan Prostate Cancer Group (PPCG)
Colin S CooperNorwich Medical School, University of East Anglia, Norwich Research Park, Norwich, UK.
Thorsten SchlommDepartment of Urology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, Berlin, Germany.ORCID http://orcid.org/0000-0001-9557-4653
Jüri ReimandDepartment of Medical Biophysics, University of Toronto, Toronto, ON, Canada.ORCID http://orcid.org/0000-0002-2299-2309
Joachim WeischenfeldtThe Finsen Laboratory, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. joachim.weischenfeldt@bric.ku.dk.ORCID http://orcid.org/0000-0002-3917-5524

Funding

Project 3: Analysis of intrinsic and extrinsic factors that promote prostate neuroendocrine differentiationP01CA265768 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MICHAEL M. SHEN · 2022 to 2026
$13.4M
Weill Cornell Medicine (WCM) SPORE in Prostate CancerP50CA211024 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI RICKMAN, DAVID S. · 2017 to 2021
$10.9M
Genomic Diversity of Prostate Cancer Across the African DiasporaR01CA259200 · NCI · DANA-FARBER CANCER INST · PI TIMOTHY RICHARD REBBECK · 2022 to 2026
$6.4M
Genomic bases for African geo-ethnic prostate cancer health disparityR01CA285772 · NCI · UNIVERSITY OF SYDNEY · PI Vanessa Marie Hayes · 2024 to 2026
$1.5M
Det Frie Forskningsråd (Danish Council for Independent Research) #8020-00282Kræftens Bekæmpelse (Danish Cancer Society) #R147-A9843NCI NIH HHS P01 CA265768NCI NIH HHS P50 CA211024NCI NIH HHS R01 CA259200NCI NIH HHS R01 CA285772Novo Nordisk Fonden (Novo Nordisk Foundation) #NNF200C0060141
6 · The paper itself

Abstract

The inactivation of tumour suppressor genes is a key step in cancer development, and is usually achieved by homozygous loss. In prostate cancer, however, large genomic regions are often hemizygously lost, which complicates the identification of putative tumour suppressors in these regions. Here, we develop Epi2Hit, an integrative computational method that leverages whole genome sequencing, epigenomic profiling and gene expression to identify biallelic inactivation of tumour suppressor genes involving DNA methylation of promoter and enhancer regions of one allele and genomic loss of the other allele. We apply Epi2Hit to a cohort of 2,021 prostate cancers to discover tumour suppressor genes. In particular, we identify epigenetic biallelic inactivation of ZFHX3 at a recurrence level similar to TP53. Biallelic inactivation of ZFHX3, a transcriptional repressor, leads to upregulation of oncogenes, including MYC and a shorter time to metastasis. Finally, we provide evidence that epigenetic silencing as 2nd hit is particularly enriched in regions with nearby essential genes, precluding homozygous loss.

Indexed as

Epigenesis, GeneticGene SilencingGenes, Tumor SuppressorProstatic NeoplasmsAllelesDNA MethylationGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansMalePromoter Regions, GeneticWhole Genome SequencingHomeodomain Proteins

Identifiers

PMID42716948
PMCPMC13558581

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.